

Infant peri-exposure prophylaxis for 12 months to eliminate breastfeeding transmission of HIV-1 in Africa. The ANRS 12174 cohort

T Tylleskär, N Nagot, C Kankasa, N Meda, J K Tumwine, J G Hofmeyr, M Mwiya, C Siuluta, H Traore, M Kwagala, et al.

▶ To cite this version:

T Tylleskär, N Nagot, C Kankasa, N Meda, J K Tumwine, et al.. Infant peri-exposure prophylaxis for 12 months to eliminate breastfeeding transmission of HIV-1 in Africa. The ANRS 12174 cohort. Conference on Retroviruses and Opportunistic Infections, Mar 2013, Atlanta, United States. hal-03922070

HAL Id: hal-03922070 https://hal.science/hal-03922070v1

Submitted on 4 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





























Summary

recommended period of breastfeeding (12 months). The ANRS 12174 study is a randomised controlled trial comparing the efficacy and safety of lopinavir/ritonavir versus lamivudine to pre-

The efficacy of infant peri-exposure prophylaxis (PreP) to prevent HIV-1 postnatal transmission has never been assessed for the entire

vent HIV-1 postnatal transmission in breastfeeding children born to HIV-1-infected mothers not eligible for ART (CD4 count above 350 cells/mL) during breastfeeding (maximum 50 weeks). HIV-uninfected children aged 7 days were randomised for either drug in a 1:1 ratio. Infant HIV-infection status was assessed at week 6, 14, 26, 38 and 50 using HIV-1 DNA PCR. The study has completed enrolment in April 2012 in Burkina Faso, Uganda, Zambia and South Africa. We report the current postnatal HIV-1 transmission rate and HIV-1 free survival in the cohort among children aged 50 weeks or more in July 2012.

By the end of July 2012, of 1273 children enrolled in the trial, 788 were aged 50 weeks or older. During this period, 8 transmissions oc-

curred representing a cumulative transmission rate of 1.1% (95%CI: 0.6-2.2). Interestingly, 6/8 transmissions occurred after 6 months of breastfeeding. Overall, 188 severe adverse events (grade 3 or more, DAIDS classification) and 22 deaths were identified. None were considered attributable to the study drugs. The overall cumulative mortality was 3.0% (95%CI: 2.0-4.5) and HIV-1-free survival was 96.0% (95%CI: 94.3-97.2).

Infant PreP is an efficacious strategy that could contribute to the elimination of HIV-1 transmission by breastfeeding.

Infant peri-exposure prophylaxis for 12 months to eliminate breastfeeding transmission of HIV-1 in Africa the ANRS 12174 cohort

T. Tylleskär, N. Nagot, C. Kankasa, N. Meda, J.K. Tumwine, J.G. Hofmeyr, M. Mwiya, C. Siuluta, H. Traore, M. Kwagala, A. Sunday, M. Singata, R. Vallo, V. Maréchal, E. Some, D. Rutagwera, D. Neboua, G. Ndeezi, D.

Neveu, D. Jackson, C. Lombard, S. Blanche, H. Sommerfelt, C. Rekacewicz and P. Van de Perre for the ANRS 12174 Trial Group

ANRS 12174 PROMISE PEP INSERM U1058 Infection by HIV and by agents with mucocutaneous tropism: from pathogenesis to prevention

UM1 - UFR de Pharmacie 15 av. C. Flahault - BP 14491 34093 MONTPELLIER Cedex 5 Tel.: +33 4 11 75 96 77/78 Fax: +33 4 11 75 97 25

Email: n-nagot@chu-montpellier.fr

to breastfed infants of HIV-infected mothers not eligible for antiretroviral therapy (ART) (i.e. CD4 count > 350 cells/µL and WHO clinical stage <3), as follows (11, 12): Option A – infant peri-exposure prophylaxis (PreP): mothers receive daily azidothymidine (AZT) during pregnancy, a single-dose nevirapine at delivery and, lamivudine plus AZT for one week post-partum. Children receive daily nevirapine (NVP) immediately after birth for a minimum of 4 to 6 weeks, until 1 week after all exposure to breast milk has ended.

Based on the goals for 2015 and on results of randomised clinical trials and interventional cohorts (1-10), the WHO presently recommends several options for prevention of HIV transmission

Option B – maternal triple antiretroviral prophylaxis (ARP): mothers receive ARP as early as 14 weeks of gestation until 1 week after all infant exposure to breast milk has ended. Option B+ - maternal ART: HIV-infected pregnant women receive lifelong ART, regardless of their clinical or immunological status.

The recommended duration of breastfeeding is 12 months, in order to reduce infant mortality and morbidity due to early weaning (13). Although option A (using either nevirapine or lamivudine) and B have both proved efficacious in clinical studies, none has administered any of the recommended prophylaxis beyond 6 months, covering only half of the WHO recommended duration of breastfeeding (12 months) for HIV-1-exposed children.

Similarly, the drug of choice for prophylaxis of breastfeeding transmission of HIV relies only on the comparison between different studies, without direct comparison between drugs. Lopinavir/ ritonavir (LPV/r), a protease inhibitor with paediatric formulation, has a greater antiviral activity than nucleosidic reverse transcriptase inhibitors or non nucleosidic reverse transcriptase inhibitors (14), and a good safety profile in young children (14-16), which makes this drug a good candidate for prophylactic purposes, despite its poor palatability.

We report on the postnatal transmission and mortality rates of WHO option A at one year of age using either LPV/r or lamivudine from an unblinded randomised trial conducted

in four African countries: Burkina Faso (Ouagadougou), Uganda (Mbale), Zambia (Lusaka) and South Africa (East London).

Material & Methods

Study design

This cohort report is based on the ANRS 12174 randomised controlled trial (ClinicalTrials.gov Identifier: NCT00640263) comparing the efficacy and safety of prolonged infant PreP with LPV/r (40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg) versus lamivudine (7.5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg) to prevent HIV-1 transmission through breast milk in children born to HIV-1-infected mothers not eligible for ART during the full duration of breastfeeding (maximum 50 weeks).

	National care				Infant trial: Day 7- Week 50													
	w <u>28</u>	Birth	Day 7	w2	w ₆	w10	w14	w18	w22	w26	w30	w34	w38	w42	w46	w50	•	
Scheduled visits	+	+	t	+	+	+	\	\	+	+	\	+	+	+	+	+		
Maternal medication		Country specific PMTCT																
Feeding counselling	Counselling on exclusive breastfeeding (EBF) Partial breastfeeding / cessation																	
	Randomisation																	
Infant medication		Specific PMTCT						PEP trial 3TC vs. LPV/r				Drugs if BF			F			
Infant HIV-1 PCR		↑	'		†		†			†			†			†		

Inclusion criteria: • breastfed at day 7

negative HIV-1 DNA PCR test result at day 7;

had received any PMTCT;

• the mother: was HIV-1 infected and was not eligible for ART and was not taking ART.

Exclusion criteria: they presented clinical symptoms and/or biological abnormalities equal to or greater than grade II of the ANRS classification for adverse event on the day of enrolment.

This picture is reproduced from Nagot N. et al., BMC Infectious Diseases, 2012, 12:246

Infant HIV-1 infection was diagnosed on DBS by means of real-time PCR detecting HIV-1 DNA (Generic HIV DNA cell, Biocentric, France) (17).

Biological assays

HIV-1 infection was confirmed on a second sample by the same technique (18).

Results

769 children included in HIV analysis

References

Figure 2. ANRS 12174 cohort profile of infants aged 50 weeks or more on July 23, 2012

randomised, double-blind, placebo-controlled trial, *Lancet* **379**, 221 (2012).


randomised controlled trial, *Lancet Infect Dis* **11**, 171 (2011).

Mitra Study, *J Acquir Immune Defic Syndr* **48**, 315 (2008).

Parity, mean (SD)

2012 in the ANRS 12174 cohort.

Kazembe, I. A. Mofolo, M. Chigwenembe, D. S. Sichali, C. M. van der Horst, Maternal or infant antiretroviral drugs to reduce HIV-1 transmission, N Engl J Med 362, 2271 (2010).



As of 23rd of July 2012, 813 infants were aged 50 weeks or more (figure 2). Among them, 25 never came back after enrolment, leaving 788 children included in the cohort analyses: 105 children from South Africa, 143 from Uganda, 166 from Burkina Faso and 374 from Zambia.

nore than 95% of mothers, except in Uganda where PMTCT was given during labour only for 24% of women. Among these 788 children, no HIV-1 testing was available after enrolment for 19 children,

682 completed the final visit; they provided 695 child-years of follow-up for the mortality outcome, and 679 for the HIV-1 outcome (figure 2).

Burkina Faso South Africa Uganda Zambia TOTAL (n=166) (n=105) (n=143) (n=374) (n=788)

Table 1. Baseline (day 7) characteristics of mothers and infants aged 50 weeks or more on the 23rd of July,

1. C. S. Chasela, M. G. Hudgens, D. J. Jamieson, D. Kayira, M. C. Hosseinipour, A. P. Kourtis, F. Martinson, G. Tegha, R. J. Knight, Y. I. Ahmed, D. D. Kamwendo, I. F. Hoffman, S. R. Ellington, Z. Kacheche, A. Soko, J. B. Wiener, S. A. Fiscus, P.

George, P. Andrew, L. M. Mofenson, S. Zwerski, Y. Maldonado, Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a

3. D. J. Jamieson, C. S. Chasela, M. G. Hudgens, C. C. King, A. P. Kourtis, D. Kayira, M. C. Hosseinipour, D. D. Kamwendo, S. R. Ellington, J. B. Wiener, S. A. Fiscus, G. Tegha, I. A. Mofolo, D. S. Sichali, L. S. Adair, R. J. Knight, F. Martinson, Z.

4. Kesho Bora Study Group, I. de Vincenzi, Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a

5. C. Kilewo, K. Karlsson, A. Massawe, E. Lyamuya, A. Swai, F. Mhalu, G. Biberfeld, Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the

6. N. I. Kumwenda, D. R. Hoover, L. M. Mofenson, M. C. Thigpen, G. Kafulafula, Q. Li, L. Mipando, K. Nkanaunena, T. Mebrahtu, M. Bulterys, M. G. Fowler, T. E. Taha, Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission,

2. H. M. Coovadia, E. R. Brown, M. G. Fowler, T. Chipato, D. Moodley, K. Manji, P. Musoke, L. Stranix-Chibanda, V. Chetty, W. Fawzi, C. Nakabiito, L. Msweli, R. Kisenge, L. Guay, A. Mwatha, D. J. Lynn, S. H. Eshleman, P. Richardson, K.

Kacheche, A. Soko, I. Hoffman, C. van der Horst, Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial, Lancet 379, 2449 (2012).

weeks). No death was deemed attributable to the study drugs.

96.0% (95%CI: 94.3-97.2) at 50 weeks

The overall median duration of any breastfeeding was 41 weeks (figure 3)

HIV-1 transmission

8 HIV-1 transmissions have been identified: 5 in Zambia, 3 in Uganda, 0 in Burkina Faso, 0 in South Africa;

→ Cumulative postnatal transmission rate: 1.1% (95%CI: 0.6-2.2). Interestingly, 6 out of 8 (75%) transmissions occurred after 6 months of breastfeeding, and 2 transmissions oc-

curred within the first six weeks.

A 9th transmission case was detected at 69 weeks after intensive search for a child who never attended any visit since enrolment. Accounting for this case, the HIV-1 transmission rate would become 1.3% (95%CI: 0.7-2.4). The HIV-1 transmission rate between day 7 and 26 weeks was 0.3% (95%CI: 0.1-1.1).

Among the 1760 mothers potentially eligible in the trial, 1484 of their babies were tested for HIV-1 and 10 were HIV-1 infected (figure 2), giving a perinatal HIV transmission of 0.67%. Therefore, the overall MTCT of full option A was 1.8% using PMTCT during pregnancy and labour as implemented by national programmes followed by our infant PreP regimens.

22 children died: 3 in Burkina Faso, 1 in South Africa, 7 in Uganda and 11 in Zambia; → Overall mortality rate: 3.0% (95%CI: 2.0-4.5).

All had a negative HIV-1 DNA PCR test when last tested, on average 7 weeks before death (min: 1 week, max: 3

HIV-1-free survival

Probability for a child to be alive without HIV-1 infection: 98.2% (95%CI: 96.9-98.9) at 26 weeks

at 50 weeks, it was the highest in South Africa (98.9%), and the worst in Uganda (92.7%) (figure 4).

Among the 788 children, 188 severe adverse events (88 clinical and 100 biological with no clinical symptoms) had been reported. In April 2012, the Independent DMC recommended continuation of follow-up without unblinding, to the end of the trial (planned in May 2013), considering that these adverse events were not grossly unbalanced between the two arms

First report of the infant PreP strategy during the recommended 12-months duration of breastfeeding with both the lowest postnatal transmission rate (1.1%, 95%CI: 0.6-2.2) and the highest HIV-1 free survival rate (96.0%, 95%CI: 94.3-97.2) ever published.

Combined with mother MTCT, option A allowed an overall MTCT below 2%, well within the target of elimination.

About three-quarters of transmissions occurred after 6 months of age, the time when all previous studies (using either infant PreP or maternal ARP) had stopped antiretrovirals. This stresses the need to obtain complete and valid efficacy data before issuing policy recommendations and choosing between the infant PreP option (A) or the maternal option (B/B+).

Our study had several limitations:

Discussion

Although still possible, it is unlikely that some deaths be attributed to undiagnosed HIV-1 infection, given the narrow period since the last HIV-1 negative test. All aspects of the infant PreP safety could not be addressed at this stage.

Comparison with maternal antiretroviral prophylaxis (ARP) trials:

The drug adherence data have not yet been analysed.

In the Kesho-Bora trial, among mothers with CD4 count ≥ 350 cells/μL, the 6-month transmission rate, when exposure to breastfeeding stopped, was 4.1% (2.0-8.3%) among mothers with maternal ARP from 28 weeks of pregnancy vs. 5.8% (3.1–10.5%) in the placebo arm (AZT during pregnancy and NVP during labour, infant single-dose NVP at birth and one week AZT after birth). These transmission rates on maternal ARP are four times higher than the MTCT in our cohort at the same time (0.67% perinatal + 0.3% postnatal transmission at 6 month, i.e. 1.0% overall).

The choice of option A or B/B+ to prevent HIV-1 postnatal transmission should be based on robust scientific grounds. Our findings should encourage maintaining infant PreP among the strategic options offered to prevent breastfeeding transmission of HIV-1. As infant PreP, in contrast to maternal ARP, can prevent cell-associated HIV-1 transmission events,(18, 19) it could avert

more residual transmission cases than maternal ARP. This could explain the large difference in HIV transmission between the Kesho-Bora trial (maternal ARP) and our study.

Conclusion

The ANRS 12174 study, covering the 12 months of recommended breastfeeding, demonstrated that the infant PreP strategy is an efficacious and safe strategy that could contribute to the elimination of HIV-1 transmission. The identification of the best drug to use for this strategy is the next outcome of this trial.

Weeks 0 10 20 30 40 47 50*

Figure 4. Life table of HIV-1 free survival by site and overall in the ANRS 12174 co-

Time to end of breastfeeding (weeks)

Figure 3. Life table of breastfeeding cessation by site and overall in the ANRS

0 10 20 30 40 47 50*

785 729 681 619 416 170 45

N Engl J Med **359**, 119 (2008). 7. C. A. Peltier, G. F. Ndayisaba, P. Lepage, J. van Griensven, V. Leroy, C. O. Pharm, P. C. Ndimubanzi, O. Courteille, V. Arendt, Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda, *AIDS* **23**, 2415 (2009). 8. R. L. Shapiro, M. D. Hughes, A. Ogwu, D. Kitch, S. Lockman, C. Moffat, J. Makhema, S. Moyo, I. Thior, K. McIntosh, E. van Widenfelt, J. Leidner, K. Powis, A. Asmelash, E. Tumbare, S. Zwerski, U. Sharma, E. Handelsman, K. Mburu, O. Jayeoba, E. Moko, S. Souda, E. Lubega, M. Akhtar, C. Wester, R. Tuomola, W. Snowden, M. Martinez-Tristani, L. Mazhani, M. Essex, Antiretroviral regimens in pregnancy and breast-feeding in Botswana, N Engl J Med 362, 2282 (2010). 8. SWEN Study group, Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials, Lancet 372, 300 (2008). 10. T. K. Thomas, R. Masaba, C. B. Borkowf, R. Ndivo, C. Zeh, A. Misore, J. Otieno, D. Jamieson, M. C. Thigpen, M. Bulterys, L. Slutsker, K. M. De Cock, P. N. Amornkul, A. E. Greenberg, M. G. Fowler, Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial, *PLoS Med* **8**, e1001015 (2011).

12. WHO, "Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants - Programmatic update" (WHO, 2012). 13. WHO, "Guidelines on HIV and infant feeding" (WHO, UNAIDS, UNFPA, UNICEF, 2010).

11. WHO, "Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendation for a pulib health approach" (WHO, 2010).

14. E. G. Chadwick, E. V. Capparelli, R. Yogev, J. A. Pinto, B. Robbins, J. H. Rodman, J. Chen, P. Palumbo, L. Serchuck, E. Smith, M. Hughes, Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24

less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy, *Pediatr Infect Dis J* 28, 215 (2009). 16. A. Violari, M. F. Cotton, D. M. Gibb, A. G. Babiker, J. Steyn, S. A. Madhi, P. Jean-Philippe, J. A. McIntyre, Early antiretroviral therapy and mortality among HIV-infected infants, N Engl J Med 359, 2233 (2008). 17. V. Avettand-Fenoel, M. L. Chaix, S. Blanche, M. Burgard, C. Floch, K. Toure, M. C. Allemon, J. Warszawski, C. Rouzioux, LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01), J Med Virol 81, 217 (2009). 18. F. Rouet, M. L. Chaix, E. Nerrienet, N. Ngo-Giang-Huong, J. C. Plantier, M. Burgard, M. Peeters, F. Damond, D. K. Ekouevi, P. Msellati, L. Ferradini, S. Rukobo, V. Marechal, N. Schvachsa, L. Wakrim, C. Rafalimanana, B. Rakotoambinina, J. P. Viard, J. M. Seigneurin, C. Rouzioux, Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse tran-

15. E. G. Chadwick, J. Pinto, R. Yogev, C. G. Alvero, M. D. Hughes, P. Palumbo, B. Robbins, R. Hazra, L. Serchuck, B. E. Heckman, L. Purdue, R. Browning, K. Luzuriaga, J. Rodman, E. Capparelli, Early initiation of lopinavir/ritonavir in infants

Competing interests The authors declare that they have no competing interests.

week results, Aids 22, 249 (2008).

scriptase polymerase chain reaction test, *J Acquir Immune Defic Syndr* **45**, 380 (2007).